Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hantavax Long-term Immunity in High Risk HFRS Population
NCT02360514Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Dec 2007
- Primary completion
- Oct 2012
- Modality
- Whole Inactivated Vaccines
01
Overview
Phase 3, open-label, single-arm trial of hantavax in hemorrhagic fever with renal syndrome (HFRS), sponsored by GC Biopharma. Primary endpoint: Antibody seroconversion rates at 1 month after the booster vaccination and its retention rates. Started Dec 2007; status: completed.
02
Drugs
hantavax
03
Conditions
hemorrhagic fever with renal syndrome (HFRS)
Beyond the preview
Go deeper on NCT02360514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360514.